Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04745143 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Monotherapy of an NMDA Enhancer for Schizophrenia

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Sep 2025 to Sep 2027
    • Study completion date: Dec 2025 to Dec 2027
    v5
  2. Re-verified, no change to tracked fieldsv4
  3. Primary completion date: Sep 2023 to Sep 2025
    • Study completion date: Dec 2023 to Dec 2025
    v3
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Previous studies found that some NMDA-enhancing agent was able to augment antioxidant activity and its adjunctive therapy was better than placebo in reducing clinical symptoms and cognitive deficits and revealed favorable safety in patients with chronic schizophrenia. Of note, a substantial portion of schizophrenia patients refuse or cannot tolerate antipsychotics due to poor response or severe side effects. Therefore, this study aims to examine the efficacy and safety of an NMDA enhancer (NMDAE) as a monotherapy for the treatment of schizophrenia.
Trial Details
NCT Number NCT04745143
Lead Sponsor China Medical University Hospital
Collaborators: National Health Research Institutes, Taiwan
Conditions
(from sponsor)		 Schizophrenia
Related terms Schizophrenia
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov